Apollo Hospitals Q2 Outcomes: PAT rises 26% YoY to Rs 477 crore

Apollo Hospitals Enterprise reported one other sturdy quarter of progress, with consolidated revenue after tax (PAT) rising 26% year-on-year (YoY) to Rs 477 crore within the September quarter (Q2FY26), pushed by broad-based enlargement throughout its healthcare, diagnostics, and digital well being verticals.

The corporate’s consolidated income grew 13% YoY to Rs 6,304 crore, supported by regular affected person volumes and margin enchancment throughout its hospital and retail healthcare segments.

Regular momentum throughout core companies

Income from Healthcare Providers (HCS) — Apollo’s hospital enterprise — rose 9% YoY to Rs 3,169 crore, with occupancy ranges bettering to 69%. The corporate reported an EBITDA of Rs 781 crore from this section, up 8% YoY, whereas PAT rose 13% YoY to Rs 410 crore, reflecting effectivity beneficial properties and powerful affected person influx for complicated procedures.

The Apollo Well being and Life-style Ltd (AHLL) section, which operates clinics and diagnostics, continued to increase, with revenues up 17% to Rs 474 crore and EBITDA bettering 21% to Rs 50 crore.

In the meantime, Apollo HealthCo, which homes the corporate’s digital well being platform Apollo 24|7 and pharma distribution enterprise, posted revenues of Rs 2,661 crore, a 17% enhance YoY, with EBITDA of Rs 110 crore. The platform’s gross merchandise worth (GMV) stood at Rs 723 crore, underscoring Apollo’s rising digital footprint in healthcare supply.

Chairman Dr Prathap C Reddy stated the corporate’s continued funding in expertise and innovation was serving to strengthen affected person care and drive operational effectivity.”We’re proud to have touched over 200 million lives and earned belief throughout 185 nations. Our early adoption of the most recent expertise has led to over 51 lakh surgical procedures, 27,000 organ transplants, and 22,000 robotic surgical procedures,” Dr Reddy stated.He added that Apollo was more and more utilizing AI-driven diagnostics and machine-learning platforms to personalise therapy for most cancers and cardiovascular sufferers. The quarter additionally noticed the corporate introduce South Asia’s first AI-based music remedy on the Apollo Proton Most cancers Centre to enhance the standard of life for most cancers sufferers present process chemotherapy.

In the course of the quarter, the Competitors Fee of India (CCI) authorised the corporate’s restructuring plan involving Apollo HealthCo, Keimed, and Apollo Healthtech, paving the way in which for Apollo to maneuver ahead with its reorganisation aimed toward unlocking shareholder worth.

The corporate additionally reiterated that capex depth will proceed to average after heavy investments in recent times, even because it continues increasing its hospital capability and scientific capabilities.